Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1943 1
2001 1
2008 2
2009 5
2010 7
2011 6
2012 8
2013 4
2014 3
2015 6
2016 24
2017 34
2018 50
2019 73
2020 133
2021 184
2022 154
2023 72
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 31101746

634 results

Results by year

Filters applied: . Clear all
Page 1
Predictors of Overall and Disease-Free Survival in Metastatic Castration-Resistant Prostate Cancer Patients Receiving 225Ac-PSMA-617 Radioligand Therapy.
Sathekge M, Bruchertseifer F, Vorster M, Lawal IO, Knoesen O, Mahapane J, Davis C, Reyneke F, Maes A, Kratochwil C, Lengana T, Giesel FL, Van de Wiele C, Morgenstern A. Sathekge M, et al. J Nucl Med. 2020 Jan;61(1):62-69. doi: 10.2967/jnumed.119.229229. Epub 2019 May 17. J Nucl Med. 2020. PMID: 31101746 Free article.
mCRPC Patients Receiving 225Ac-PSMA-617 Therapy in the Post-Androgen Deprivation Therapy Setting: Response to Treatment and Survival Analysis.
Sathekge M, Bruchertseifer F, Vorster M, Lawal IO, Knoesen O, Mahapane J, Davis C, Mdlophane A, Maes A, Mokoala K, Mathabe K, Van C, Wiele D, Morgenstern A. Sathekge M, et al. J Nucl Med. 2022 Oct;63(10):1496-1502. doi: 10.2967/jnumed.121.263618. Epub 2022 Feb 17. J Nucl Med. 2022. PMID: 35177427 Free PMC article.
Therapeutic efficacy, prognostic variables and clinical outcome of 177Lu-PSMA-617 PRLT in progressive mCRPC following multiple lines of treatment: prognostic implications of high FDG uptake on dual tracer PET-CT vis-à-vis Gleason score in such cohort.
Suman S, Parghane RV, Joshi A, Prabhash K, Bakshi G, Talole S, Banerjee S, Basu S. Suman S, et al. Br J Radiol. 2019 Dec;92(1104):20190380. doi: 10.1259/bjr.20190380. Epub 2019 Nov 1. Br J Radiol. 2019. PMID: 31600089 Free PMC article.
Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of 177Lu-PSMA-617 Theranostics in Metastatic Castration-Resistant Prostate Cancer.
Violet J, Sandhu S, Iravani A, Ferdinandus J, Thang SP, Kong G, Kumar AR, Akhurst T, Pattison DA, Beaulieu A, Mooi J, Tran B, Guo C, Kalff V, Murphy DG, Jackson P, Eu P, Scalzo M, Williams S, Hicks RJ, Hofman MS. Violet J, et al. J Nucl Med. 2020 Jun;61(6):857-865. doi: 10.2967/jnumed.119.236414. Epub 2019 Nov 15. J Nucl Med. 2020. PMID: 31732676 Free PMC article. Clinical Trial.
The Prognostic Value of Posttreatment 68Ga-PSMA-11 PET/CT and 18F-FDG PET/CT in Metastatic Castration-Resistant Prostate Cancer Treated with 177Lu-PSMA-617 and NOX66 in a Phase I/II Trial (LuPIN).
Pathmanandavel S, Crumbaker M, Nguyen A, Yam AO, Wilson P, Niman R, Ayers M, Sharma S, Eu P, Martin AJ, Stockler MR, Joshua AM, Emmett L. Pathmanandavel S, et al. J Nucl Med. 2023 Jan;64(1):69-74. doi: 10.2967/jnumed.122.264104. Epub 2022 Jun 23. J Nucl Med. 2023. PMID: 35738906 Free PMC article. Clinical Trial.
Activity and Adverse Events of Actinium-225-PSMA-617 in Advanced Metastatic Castration-resistant Prostate Cancer After Failure of Lutetium-177-PSMA.
Feuerecker B, Tauber R, Knorr K, Heck M, Beheshti A, Seidl C, Bruchertseifer F, Pickhard A, Gafita A, Kratochwil C, Retz M, Gschwend JE, Weber WA, D'Alessandria C, Morgenstern A, Eiber M. Feuerecker B, et al. Eur Urol. 2021 Mar;79(3):343-350. doi: 10.1016/j.eururo.2020.11.013. Epub 2020 Dec 5. Eur Urol. 2021. PMID: 33293081
Response assessment using 68Ga-PSMA ligand PET in patients undergoing 177Lu-PSMA radioligand therapy for metastatic castration-resistant prostate cancer.
Grubmüller B, Senn D, Kramer G, Baltzer P, D'Andrea D, Grubmüller KH, Mitterhauser M, Eidherr H, Haug AR, Wadsak W, Pfaff S, Shariat SF, Hacker M, Hartenbach M. Grubmüller B, et al. Eur J Nucl Med Mol Imaging. 2019 May;46(5):1063-1072. doi: 10.1007/s00259-018-4236-4. Epub 2018 Dec 19. Eur J Nucl Med Mol Imaging. 2019. PMID: 30569186 Free PMC article.
Evaluation of 177Lu-PSMA-617 SPECT/CT Quantitation as a Response Biomarker Within a Prospective 177Lu-PSMA-617 and NOX66 Combination Trial (LuPIN).
Pathmanandavel S, Crumbaker M, Ho B, Yam AO, Wilson P, Niman R, Ayers M, Sharma S, Hickey A, Eu P, Stockler M, Martin AJ, Joshua AM, Nguyen A, Emmett L. Pathmanandavel S, et al. J Nucl Med. 2023 Feb;64(2):221-226. doi: 10.2967/jnumed.122.264398. Epub 2022 Aug 25. J Nucl Med. 2023. PMID: 36008120 Free PMC article.
634 results